In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...
Pharmaceutical Technology on MSN8h
Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancersThe European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a ...
Louisville Public Media on MSN2d
Eli Lilly's Alzheimer's drug not recommended by top European regulatorEli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...
Needham analyst Gil Blum lowered the firm’s price target on Sarepta (SRPT) to $183 from $202 and keeps a Buy rating on the ...
After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...
Mizuho says that while “any clinical hold is concerning,” the European Medicines Agency’s request to pause the three Elevidys studies will ...
The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...
Weight loss drugs such as semaglutide, found in Ozempic and Wegovy, are tied to a 40% reduced risk of an Alzheimer's disease ...
A key result of a workshop series of European regulatory authorities and HTA agencies: Drug studies should be designed in such a way that they address both regulatory questions and the essential ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback